Gram-negative Bacteremia in Children With Hematologic Malignancies and Following Hematopoietic Stem Cell Transplantation: Epidemiology, Resistance, and Outcome.


Journal

Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928

Informations de publication

Date de publication:
Nov 2019
Historique:
pubmed: 19 7 2019
medline: 15 4 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Gram-negative rod (GNR) infections adversely affect the outcome of patients with malignancies and following hematopoietic stem cell transplantation (HSCT). This retrospective observational study aimed to describe the epidemiology, outcome, and resistance patterns of GNR bacteremia in children with hematologic malignancies (HM) and after HSCT during the period spanning from 2010 to 2014 in a tertiary children's hospital. A total of 270 children were included in the analysis; 65 (24%) developed 85 episodes of GNR bacteremia; the rate was 36/122 (29.5%) in post-HSCT and 29/178 (16.3%) in HM patients (P<0.05). Overall, 10% of the GNRs were carbapenem resistant. In multivariate analysis, prolonged neutropenia (≥7 d; odds ratio: 19.5, 95% confidence interval: 2.6-148.4) and total hospitalization for a duration of >30 days in the last 3 months (odds ratio: 17.5, 95% confidence interval: 1.4-224.4) were associated with carbapenem-resistant GNR bacteremia. Thirty-day mortality following GNR bacteremia was 0% in HM and 7/52 episodes (13.5%) in HSCT patients (P<0.05). Carbapenem-resistant versus carbapenem-sensitive bacteremia was associated with longer duration of bacteremia (mean: 3.8 vs. 1.7 d), higher risk for intensive care unit hospitalization (44.4% vs. 10.1%), and higher mortality rate (33% vs. 5.8%) (P<0.05). To summarize, GNR bacteremia was frequent, especially in post-HSCT children. Carbapenem resistance adversely affects patients' outcome, increasing morbidity and mortality. Empirical antibiotic therapy must be adjusted to the local resistance patterns.

Identifiants

pubmed: 31318820
doi: 10.1097/MPH.0000000000001556
doi:

Substances chimiques

Drug Combinations 0
Gentamicins 0
trimethoprim, sulfadoxine drug combination 39295-60-8
Sulfadoxine 88463U4SM5
Trimethoprim AN164J8Y0X
Piperacillin X00B0D5O0E

Types de publication

Clinical Trial Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e493-e498

Auteurs

Michal Vinker-Shuster (M)

Pediatric Infectious Diseases Unit.

Polina Stepensky (P)

Departments of Stem Cell Transplantation.

Violeta Temper (V)

Clinical Microbiology and Infectious Diseases.

Reem Masarwa (R)

Division of Clinical Pharmacy, School of Pharmacy, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Diana Averbuch (D)

Pediatric Infectious Diseases Unit.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH